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Abstract
Background: A clinical heterogeneity was reported in patients with Cystic Fibrosis (CF) with the same CFTR
genotype and between siblings with CF.
Methods: We investigated all clinical aspects in a cohort of 101 pairs of siblings with CF (including 6 triplets)
followed since diagnosis.
Results: Severe lung disease had a 22.2% concordance in sib-pairs, occurred early and the FEV1% at 12 years
was predictive of the severity of lung disease in the adulthood. Similarly, CF liver disease occurred early (median: 15
years) and showed a concordance of 27.8% in sib-pairs suggesting a scarce contribution of genetic factors; in fact, only
2/15 patients with liver disease in discordant sib-pairs had a deficiency of alpha-1-antitrypsin (a known modifier gene
of CF liver phenotype). CF related diabetes was found in 22 pairs (in 6 in both the siblings). It occurred later (median:
32.5 years) and is strongly associated with liver disease. Colonization by P. aeruginosa and nasal polyposis that required
surgery had a concordance > 50% in sib-pairs and were poorly correlated to other clinical parameters. The pancreatic
status was highly concordant in pairs of siblings (i.e., 95.1%) but a different pancreatic status was observed in patients
with the same CFTR mutations. This suggests a close relationship of the pancreatic status with the “whole” CFTR
genotype, including mutations in regulatory regions that may modulate the levels of CFTR expression. Finally, a
severe course of CF was evident in a number of patients with pancreatic sufficiency.
Conclusions: Physicians involved in care of patients with CF and in genetic counseling must be aware of the clinical
heterogeneity of CF even in sib-pairs that, at the state of the art, is difficult to explain.
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Background
Cystic fibrosis (CF) is the most common, severe, auto-
somal recessive inherited disease among Caucasians [1].
It is usually characterized by elevated sweat chloride
levels (SCL), pancreatic insufficiency (PI), progressive
lung disease with chronic bacterial infections of lower
airways and male infertility due to obstructive azoosper-
mia. More than 2000 variants have been identified in the
cystic fibrosis transmembrane conductance regulator
(CFTR) gene so far (www.genet.sickkids.on.ca), but only
few have been functionally characterized [2]. Some of
them may be grouped in six classes according to the
known effect on CFTR synthesis and/or function [2, 3].
However, although life-expectance and severity of the
disease depend on the class of mutations [4, 5], there is
a wide clinical heterogeneity in CF patients carrying the
same CFTR genotype and even between siblings and
twins with CF [6]. Several sources contribute to such
variability as mutations in non-coding regions of the
CFTR gene [7–9], intronic variants [9–11] and complex
alleles [12, 13] making the genotype-phenotype rela-
tionship more complex.
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In the last decade several studies explored the role of
modifier genes of CF phenotype [14] for meconium
ileus (MI) [15–17], CF-related diabetes (CFRD) [18], CF
liver disease (CFLD) [19], lung disease [20, 21] and the
colonization by P. aeruginosa [22]. However, environ-
mental factors, such as the quality of health care, com-
pliance to therapy [23], lifestyle, and socio-economic
status [24] play a pivotal role in the outcome of CF.
The strong heterogeneity of CF impacts on the genetic
counseling and on the reproductive planning of families
that have CF affected children. In the present study, we
evaluated a series of pairs of siblings with CF monitored
since diagnosis to study the degree of clinical heterogen-
eity of the CF phenotype, assessing and correlating clin-
ical aspects and complications of the disease.
Methods
Patients
The study population consisted of patients followed
since diagnosis at 12 CF specialized care centers in Italy
who met diagnostic criteria for CF [25] and had at least
one sibling suffering from CF. According to the current
Italian legislation, we obtained from all patients (or from
their legal guardian) the informed consent to use an-
onymously clinical data for research purposes.
Methods
Sweat chloride levels were tested according to guidelines
[26]. We screened for a panel of mutations and for the
most common CFTR rearrangements [27]; thus, we car-
ried out gene sequencing (detection rate 95%) [28, 29]
in patients in which one or both mutations resulted un-
detected after first level analysis [30]. We analyzed 7 in-
tragenic CFTR short tandem repeats [31] to verify that
both members of four sibling-pairs carrying only one
known mutation had the same CFTR genotype. Mo-
lecular analysis revealed more than 50 different CFTR
mutations in our patients and only for a half of them
functional studies had defined the molecular effect and
the class; furthermore, some of these latter mutations
may combine more defects and can be attributed to
more classes [2]. Thus, we did not perform correlations
between the CFTR genotype and clinical parameters.
However, Additional file 1: Table S1 provides the CFTR
genotype of each patient included in the study.
Meconium ileus was defined using the criteria de-
scribed [15]. The forced expiratory volume (FEV1),
expressed as the percentage of predicted value for age,
according to standardized reference equations for spir-
ometry [32] was recorded. To avoid age-related differ-
ences between siblings of each pair, we recorded as
current FEV1 the last value of the younger sibling
and that of the older sibling at the same age. In the
case of patients who had died or had undergone lung
transplantation we recorded the last FEV1 and the
value of the living or non-transplanted member of the
sibling-pair at the same age. Given the inter-individual
variability of FEV1 and the evolution of lung damage
with age [33] the patients were classified as severe or
mild according with the criteria by Schluchter et al.,
that take into account both the FEV1 value and age
[34, 35]. The airway colonization by P. aeruginosa was
identified by sputum or oropharyngeal swab culture.
Chronic infection was defined according to the modi-
fied Leeds criteria [36].
Fecal pancreatic elastase was evaluated annually and at
least 3 months before enrollment. Pancreatic sufficiency
was defined on the basis of fecal pancreatic elastase-1
higher than 200 mcg/g measured in the absence of acute
pancreatitis or gastrointestinal diseases. Pancreatitis was
defined as acute or chronic according to the report from
International study group of pediatric pancreatitis [37]
excluding all known causes of pancreatitis. Liver disease
was evaluated by means of clinical, biochemical or ultra-
sonography abnormalities recorded in two consecutive
examinations within a 3-month period, in the absence of
other causes of congenital or acquired chronic liver dis-
ease [38]. Patients were considered as affected by CFLD
when they had liver cirrhosis, considered as the extreme
phenotype to define liver disease in our study, with im-
aging techniques showing nodular hepatic parenchyma
and signs of portal hypertension [17]. A glucose toler-
ance test was performed annually in all patients with CF
and the diagnosis of CFRD was made according to the
standard American Diabetes Association criteria [39]. Fi-
nally, the history of nasal polyposis requiring surgery
was evaluated.
Statistics
The concordance for disease (symptoms or complica-
tions) within sibling-pairs was calculated as the ratio be-
tween the number of pairs concordant for the symptom/
complication and the number of pairs in which at least
one member had the symptom/complication [15].
Results and discussion
Study population
We studied 208 patients with CF (median age: 30 years,
range 12–61 years; 106 males); of these, 40 (19.2%) were
diagnosed by newborn screening (NBS) and 168 (80.8%)
by symptoms or by family history. All the 208 patients
were over 12 years of age and 172/208 patients (82.7%)
were over 18 years. The study included 95 pairs of sib-
lings (22 pairs of females, 27 pairs of males and 46 pairs
of one female and one male) and 6 sets of 3 siblings (2
including two males and one female, 2 including two
females and one male and 2 including three females).
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In 80/101 pairs (79.2%) all the siblings were above 18
years of age.
Pancreatic status
As shown in Table 1, in our pairs of siblings we found
a concordance for PI of 95.1% (i.e., only in three
sibling-pairs the pancreatic status resulted discordant)
confirming the known correlation between the pancre-
atic status and the CFTR genotype. However, pairs of
siblings with the same CFTR mutations may have PS or
PI, and it is known that mutations like the R334W, the
R347P, the 2789 + 5G > A [40], or the D1152H [41] may
be associated with PS or PI. This means that the high
degree of concordance for the pancreatic status found
in siblings depends on the “whole” CFTR genotype
(that is quite completely shared by siblings) including
either mutations in the coding regions and variants in
non-coding regions like the promoter or the intronic
regions [7, 8] that together define the levels of residual
activity of the CFTR protein at pancreatic level and
thus may modulate the pancreatic status of each patient.
Table 1 compares the clinical characteristics and the
complications in sib-pairs with different pancreatic
status. In sib-pairs with PI, MI, severe lung disease,
CFLD and CFRD occurred more frequently (even if
the small number of cases preclude a statistical com-
parison) according to the current literature [42, 43].
Recurrent pancreatitis was significantly more frequent
in sib-pairs with PS in agreement with the concept
that recurrent pancreatitis in patients with CF is due
to ductal plugging that typically occurs in patients
with PS [43, 44]. On the other hand, modifier genes
other than CFTR may enhance the risk to develop re-
current/chronic pancreatitis [45, 46] explaining some
cases of patients with PI that developed recurrent pan-
creatitis (Additional file 1: Table S1).
Interestingly, among the patients with PS we found MI
in 2 cases, severe lung disease in 6 and complications
such CFLD in 5 or CFRD in 7 cases (Additional file 1:
Table S1). We are confident that our patients with PS
would not develop PI later either because most patients
with PS have at least one mild mutation and because
their age is higher than that of patients with PI (mean
34.6 years, median 33 years for patients with PS versus a
mean age of 28.0 years and a median of 25 years of pa-
tients with PI). Thus, a severe clinical phenotype may
occur in a percentage of patients with PS. Considering
that most patients with CF and PS are nowadays diag-
nosed by NBS, the presence of these complicated cases
suggests that patients with PS would be monitored with
the same care of patients with PI.
Meconium ileus and DIOS
We found a 36.4% of concordance for MI in sib-pairs,
i.e., 4 pairs were concordant for MI and 7 pairs were dis-
cordant suggesting that in addition to the CFTR geno-
type other non-genetic and genetic factors contribute to
the development of MI. Among the genetic ones, in
CFTR-deficient mice, that is an excellent model for hu-
man MI, three potential modifier loci for MI were found
on chromosomes 1, 9 and 10, respectively [47]. Subse-
quent studies in humans identified at least 2 modifier
loci for MI [15] and thus, the SLC4A4 gene was candi-
date as modifier genes for MI in patients with CF [48].
Furthermore, a role of KCNN4 as a modifier gene of MI
was suggested [16, 17].
We found five patients with CF that had DIOS; such
complication was revealed in both the members of two
sib-pairs and in a member of a further pair (Additional
file 1: Table S1). Interestingly, none of the five patients
experienced MI, reinforcing the view that DIOS, once
considered the adult equivalent of MI, has an independ-
ent etiology [15].
Lung disease
We found 34/208 patients (16.4%) with severe lung
disease. The concordance for severe lung disease was
22.2%, i.e., in 21 pairs the lung status was discordant
(i.e., severe versus mild) between siblings (Fig. 1) while
in 6 pairs both the siblings had a severe lung disease
suggesting that environmental factors and genes inherited
Table 1 Concordance within sib-pairs for PI and correlation
between the pancreatic status and meconium ileus (MI),
severity of lung disease, CF liver disease (CFLD), CF related
diabetes (CFRD) and recurrent panreatitis (RP) in 101 pairs
of siblings with CF. N: absence of the symptom/complication
Concordance within sib-pairs for PI (%)95.1
PI/PI PI/PS PS/PS
Number of sib-pairs 58 3 40
Meconium ileus: MI/MI 4 0 0
MI/N 5 0 2
N/N 49 3 38
Lung disease: Severe/severe 6 0 0
Severe/mild 15 1 5
Mild/mild 37 2 35
CF liver disease: CFLD/CFLD 3 2 0
CFLD/N 11 0 2
N/N 44 1 38
CF related diabetes: CFRD/CFRD 5 0 1
CFRD/N 11 3 2
N/N 42 0 37
Pancreatitis: RP/RP 1 0 1
RP/N 1 0 6
N/N 56 3 33
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independently by CFTR contribute to the pathogenesis
of severe lung disease. This agree with the results of
Vanscoy et al. on 231 pairs of siblings [49], and of Col-
laco et al. [21], that concluded that genetic and envir-
onmental factors contribute equally to lung function in
patients with CF. Finally, an excellent study on 6365 pa-
tients with CF revealed five loci that modulate the severity
of lung disease in patients with CF [20]. The severe lung
disease correlated with PI (e.g., all the 6 pairs of siblings
with severe lung disease had PI, see Additional file
1: Table S1) and with P. aeruginosa colonization (see
below).
It is interesting to observe the longitudinal data of 25
patients from our study for which the values of FEV1
at the age of 12 years and at the age of 25 years or
later were available (Fig. 2). Even if the number of
cases is small, the classification of severe (n = 12) or
mild (n = 13) lung disease performed at 12 years in-
variably coincides with that obtained in the adult-
hood in the same patient, suggesting that the FEV1%
in young patients with CF is predictive of the lung
function in the adult age.
On the other hand, it is known that structural lung
damage is an early event in patients with CF [50]. This
was revealed by high-resolution chest tomography [51]
and by the presence of severe pulmonary inflammation
and structural lung disease in still asymptomatic pa-
tients diagnosed by NBS [52].
Colonization by Pseudomonas aeruginosa
We found colonization by P. aeruginosa in 92/208 (44.2%)
patients with CF. Among our 101 pairs of siblings, we
found colonization by P. aeruginosa in all the members of
34 sibling-pairs, among which the three siblings of two
triplets and only one member of 20 sibling-pairs (and
in two of three members of a triplet), with a high con-
cordance for colonization (i.e., 61.8%). This result
agrees with previous studies on 50 [52] and 11 [19]
pairs of siblings. Interestingly, among our siblings dis-
cordant for colonization, in 11/21 cases both the sib-
lings lived in the same house, and the sibling colonized
by P. aeruginosa was colonized since at least 3 years.
These data indicate a limited role of the environment
in the colonization and confirms a contribution of
CFTR genotype and genes inherited independently by
CFTR that may predispose to colonization by P. aerugi-
nosa, as reviewed by Cutting [3]. Nevertheless, we can-
not rule out an early intervention (e.g. antibiotics) to
prevent nosocomial infection in non-colonized siblings.
In patients with colonization there is a significantly
higher occurrence of severe lung disease (data not
shown). However, colonization is likely a consequence
of the severe pulmonary damage more than a causal
contribution. Indeed, the mean age of colonization in
our patients was 18.5 years (median 22.6), while the
occurrence of the structural lung damage is an early
Fig. 1 FEV1% of predicted for age in 21 pairs of siblings with cystic
fibrosis discordant for the severity of lung disease. The classification
as mild or severe was performed according to the criteria by
Schluchter et al. [30] that take into account both the FEV1 value
and age
Fig. 2 FEV1% of predicted for age in 25 patients with cystic fibrosis.
For each patient we report the value measured at the age of 12
years and the current value at the age of 25 years or later. The
classification of mild (13 cases) or severe (12 cases) was performed
according to criteria by Schluchter et al. [30] that take into account
both the FEV1 value and age
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event in patients with CF (as discussed in the previous
paragraph).
CF liver disease
We found CFLD in 24/208 (11.5%) patients with CF. It
is difficult to compare this figure with previous data be-
cause different parameters may be used to define CFLD
(i.e., altered aminotransferase levels, focal biliary cirrho-
sis, US alterations, portal hypertension). As described in
materials and methods, we used very stringent parame-
ters to define CFLD and our results agree with the evi-
dence that about 10% of patients with CF develop a
severe liver damage and about 5% require liver trans-
plantation. Our data confirm that CFLD is an early event
since it was diagnosed at a mean age of 14.7 years (me-
dian 15 years old, range 7–27 years) in agreement with
the view that CFLD peaks in adolescence [42].
CFLD was found in both the members of 5 sibling-
pairs and in one member of 13 sibling-pairs (among
which two triplets) and in two members of a further
triplet. No previous data are available on the comparison
of CFLD liver disease in siblings and in twins with CF,
but the concordance for CFLD of 27.8% obtained in our
sibling-pairs indicate a scarce contribution of genes in
the pathogenesis of CFLD reinforcing the role of envir-
onmental, mostly still unknown, risk factors [38]. In fact,
the largest two-stage control study (about 2000 patients
with CF) on modifier genes of CFLD revealed mutations
in the SERPIN1 gene encoding for alpha-1-antitrypsin
only in about 2% of patients with CFLD [19]. In agree-
ment, among the 15 sibling-pairs discordant for CFLD,
only in 2 cases the sibling suffering from CFLD had
levels of serum alpha-1-antitrypsin under the lower ref-
erence limit, compatible with the deficiency of the pro-
tein, while the siblings free from CFLD had normal
levels of the protein.
Cystic fibrosis related diabetes (CFRD)
We found CFRD in all the members of 6/101 sibling-
pairs (among which one triplet) and in one member of
16/101 sibling-pairs. The concordance for CFRD was
27.3% and this figure compares with that of 18.0% re-
ported in a population of 588 sibling-pairs [53]. These
data, added to the concordance for CFRD of 73.0% ob-
tained in 68 pairs of monozygotic twins with CF [53]
that share 100% of DNA, support the view that genetic
modifiers play a marginal role in the development of
diabetes in patients with CF. This is also confirmed by
the observation that the occurrence of CFRD is not an
early complication in patients with CF [39]. In fact, the
diagnosis of CFRD in our patients was performed at the
mean age of 32.2 years and in more than a half of pa-
tients > 30 years. Furthermore, we excluded also the
gender as a risk factor for CFRD: we found such
complication in 13/106 males and in 15/102 females (p
not significant). Most studies on larger populations re-
ported the female gender as a risk factor for CFRD
[42], but a more recent study on 588 sibling-pairs did
not find a statistically significant role of gender as risk
factor for CFRD [53].
As shown in Table 1, PI was significantly more fre-
quent in sib-pairs with CFRD, confirming PI as a risk
factor for CFRD since it causes a progressive pancreatic
fibrosis that gradually damages the insulae [54]. How-
ever, observing that 7/28 patients with CFRD had PS
(Additional file 1: Table S1), we suggest that also CF pa-
tients with PS must be included in the annual screening
for CFRD based on the glucose tolerance test [42].
In addition, CFLD contributes to the risk for CFRD
[55] since we found a higher occurrence of CFLD among
sib-pairs with CFRD than in those free from this compli-
cation. Finally, our data are in agreement with the view
that severe lung disease is a risk factor for CFRD in turn
[56, 57]. In fact, in 19 sib-pairs in which one or both pa-
tients had CFRD, in 12 cases one or both the siblings
had a severe lung disease, a condition observed only in
15/79 pairs in which both the siblings were free from
CFRD. This correlation is more evident in 16 sibling-
pairs discordant for CFRD, in which the sibling with
CFRD, at the same age, had the worst FEV1% (p = 0.004,
Wilcoxon signed rank test) in 14/16 cases (Fig. 3).
Nasal polyposis
We found nasal polyposis requiring surgery in both the
siblings of 13 pairs and only in one sibling from 12
sibling-pairs (concordance for disease: 52.0%). There
are no previous data on sibling pairs to which compare
our results. The poor correlation of nasal polyposis to
other clinical manifestations such as the pancreatic sta-
tus and the severity of lung disease (data not shown)
imply that modifier genes play a role in determining
nasal polyposis. In fact, a recent study firstly described
the potential role of interferon-related developmental
regulator 1 (a known modifier gene for CF pulmonary
disease severity) as a modifier gene of nasal polyposis
in patients with CF [58].
Conclusions
Our study confirms the clinical heterogeneity of CF also
in a percentage of pairs of siblings with CF. Physicians
involved in genetic counseling must be aware of a so
wide and mostly unpredictable variability. Stochastic, en-
vironmental and genetic factors also independent by
CFTR contribute to such variability, even if with a differ-
ent weight on each variable (i.e., nasal polyposis and P.
aeruginosa colonization may be more influenced by gen-
etic factors while CFRD and CFLD or the severe lung
disease may be influenced either by genetic and by
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environmental factors). However other variables like
medical care (that significantly improved in the last
years), strongly influenced the clinical expression of
each patient of our cohort that includes CF patients in
the wide range between 12 to 61 years. Some working
hypotheses emerged from our study: i) the classifica-
tion of the lung damage as severe or mild based on
the FEV1% assessed at the age of 12 years coincides
with that obtained in the adulthood; ii) CFRD is influ-
enced by the severity of liver disease; iii) a severe
course of the disease (including the occurrence of
complications) may occur in a percentage of patients
with CF and PS suggesting that also such cases, usu-
ally revealed by NBS and once classified as mild CF,
should be monitored as the patients with PI.
Additional file
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